| Company Name: | Array BioPharma, Inc. | | Ticker Symbol: | ARRY | | | WWW Address: | www.arraybiopharma.com |
| CEO: | Ron Squarer | | No. of Employees: | 250 |
| Common Issue Type: | CS | | Business Description: | Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 5.85 |  0.195 | 5.72 | 5.89 | 5.63 | 5.73 | 5.52 | 547693 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 683.1 | 116.8 | 1.62 | -0.33 | 0.00 | 0.0 | 0.0 | 6.56 - 3.00 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 5.66 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 683.1 | mil |
| Latest Shares Outstanding | 116.8 | mil |
| Earnings pS (EPS) | -0.33 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 340,540 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 85.3 | mil |
| Float as % of Shares Outstanding | 92.6 | % |
| Foreign Sales | 14 | mil |
| Domestic Sales | 71 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 29.10 | % |
| Research & Devlopment (R&D) as % of Revenue | 88.60 | % |
| Gross Profit Margin | 61.8 | % |
| EBITDA Margin | -55.9 | % |
| Pre-Tax Profit Margin | -80.7 | % |
| Assets Turnover | 0.6 | % |
| Return on Assets (ROA) | -48.7 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -121.9 | % |
| Current Ratio | 1.7 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 222.0 | % |
| Working Capital pS | 0.34 | $ |
| Cash pS | 0.38 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -0.45 | $ |
| Cash Flow pS | -0.41 | $ |
| Free Cash Flow pS | -0.73 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -12.61 | |
| Price/Cash Flow | -13.8 | |
| Price/Free Cash Flow | -7.7 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -3.9 | 97 | 11,344 | 45,513 |
| 4 Weeks | 6.18 | 5.04 | 5.98 | -5.4 | 91 | 11,986 | 227,734 |
| 13 Weeks | 6.56 | 3.69 | 4.07 | 39.1 | 128 | 11,354 | 715,294 |
| 26 Weeks | 6.56 | 3.30 | 3.40 | 66.5 | 142 | 10,778 | 1,336,494 |
| 52 Weeks | 6.56 | 3.00 | 3.46 | 63.6 | 131 | 10,739 | 2,663,294 |
| YTD | 6.56 | 3.66 | - | 52.2 | 131 | 9,729 | 963,132 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 5.78 | 5.76 | 5.36 | 4.38 | 4.65 | 1.62 | 1.73 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 25.46 | 73.2 | 12.20 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | -31.52 | NA | -15.89 |
| R&D | -8.13 | NA | -9.51 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -31.5 | -47.9 | 18.4 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.18 | -0.08 | 0.69 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 15.89 |
| Current Ratio | 1.2 |
| Quick Ratio (Acid Test) | 1.2 |
| Liquidity Ratio (Cash) | 1.17 |
| Receivables Turnover | 0.0 |
| Average Collection Period | |
| Working Capital/Equity | -18.3 |
| Working Capital pS | 0.19 |
| Cash-Flow pS | -0.20 |
| Free Cash-Flow pS | -0.38 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.37 |
| Financial Leverage Ratio (Assets/Equity) | 0.0 |
| Debt Ratio | 179.4 |
| Total Debt/Equity (Gearing Ratio) | 0.00 |
| LT Debt/Equity | 0.00 |
| LT Debt/Capital Invested | 1,872.1 |
| LT Debt/Total Liabilities | 47.5 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 36.17 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 26.72 |
| Tobin's Q Ratio | 6.12 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -129.58 |
| Enterprise Value (EV)/Free Cash Flow | -19.01 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -12.61 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | -13.8 |
| Price/Free Cash Flow Ratio - LTM | -7.7 |
| Price/Sales Ratio | 10.20 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 1.00 |
| Current Liabilities pS | 0.82 |
| Tangible Book Value pS - LTM | -0.45 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 0.05 |
| Cash pS - LTM | 0.38 |
| Cash Flow pS - LTM | -0.41 |
| Free Cash Flow pS - LTM | -0.73 |
| Earnings pS (EPS) | -0.33 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -41.09 |
| Free Cash Flow Margin 5YEAR AVG | -135.23 |
| Net Profit Margin | -27.7 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | -0.91 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 13.51 |
| Return on Capital Invested (ROCI) | -374.3 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -1237.9 |
| Assets Productivity | 0.90 |
| Return on Assets (ROA) | -21.8 |
| Return on Assets (ROA) - 5YEAR AVRG. | -62.1 |
| Gross Profit Margin | 61.8 |
| Gross Profit Margin - 5YEAR AVRG. | 66.0 |
| EBITDA Margin - LTM | -55.9 |
| EBIT Margin - LTM | -64.3 |
| Pre-Tax Profit Margin | -27.7 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | |
| Revenue per Employee | 340,540 |
| Net Income per Employee | -94,324 |
| Average Collection Period | |
| Receivables Turnover | 0.0 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 7.59 |
| Assets/Revenue | 1.11 |
| Net Working Capital Turnover | 4.96 |
| Fixed Assets Turnover | 5.69 |
| Total Assets Turnover | 0.9 |
| Revenue per $ Cash | 1.53 |
| Revenue per $ Plant | 7.06 |
| Revenue per $ Common Equity | -0.91 |
| Revenue per $ Capital Invested | 13.51 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 17.9 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 31.1 |
| Research & Devlopment (R&D) as % of Revenue | 66.6 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 66.6 |
|
|  
|
| |
 |  |
